Semaglutide · source year
32 selected, source-linked Semaglutide records carrying a 2025 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
32 selected records.
2 represented types.
32 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05702931 at 2026-07-30T18:18:33.515Z. Its registry update date was 2025-12-29, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 218316 with status AP dated 2025-12-22, and names semaglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05891587 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07280221 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04102189 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-11, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 13 for the reviewed Semaglutide label family with a published date of 2025-12-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04788511 at 2026-07-30T18:18:33.488Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07239570 at 2026-07-30T18:19:48.218Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 12 for the reviewed Semaglutide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06499857 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-14, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06446531 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2025-19345, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04466345 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-02, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06639464 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-26, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05548647 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 11 for the reviewed Semaglutide label family with a published date of 2025-08-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06986993 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06691243 at 2026-07-30T18:23:09.829Z. Its registry update date was 2025-08-24, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05895643 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-05, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07090343 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-29, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04451837 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07043361 at 2026-07-30T18:24:37.183Z. Its registry update date was 2025-07-09, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07018544 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06937060 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-13, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06959784 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-07, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04889183 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-22, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05302596 at 2026-07-30T18:29:04.234Z. Its registry update date was 2025-04-17, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05520775 at 2026-07-30T18:29:04.228Z. Its registry update date was 2025-04-02, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04873050 at 2026-07-30T18:30:10.991Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06764056 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-08, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗